All Stories

Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic

Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.

Mar 17, 2025 - 13:18
 0
Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic
Otsuka’s Taiho Pharmaceutical is paying $400 million upfront to acquire Switzerland’s Araris Biotech and its antibody-drug conjugate linker platform.
Read More

Tags:

Previous Article

Citygate diversifies with launch of new leasing business

Next Article

Q Energy to build 200MW solar PV in Spain

Related Posts

DOGE terminates leases for 30 FDA sites across 23 states

DOGE terminates leases for 30 FDA sites across 23 states

Mar 4, 2025  0

Vir, awaiting ‘functional cure’ data for hep B combo, won’t take treatment forward alone

Vir, awaiting ‘functional cure’ data for hep B combo, w...

Feb 27, 2025  0

Harbour offshoot pens $395M biobucks deal for preclinical rival to Neurocrine’s Crenessity

Harbour offshoot pens $395M biobucks deal for preclinic...

Feb 26, 2025  0